One picture explains the sky-high $22.95 million compensation for Hims CEO, Du Ge. On April 28th and 29th (Eastern Time), Hims' stock price fell over 10% after disclosing that CEO Andrew Dudum's 2025 compensation reached $22.95 million (272 times the median employee pay). Although the company achieved most of its performance targets, this compensation structure sparked investor dissatisfaction during a sensitive period when the company is transitioning to the GLP-1 weight-loss drug market and facing competition from Amazon. While most of the compensation is equity incentives, theoretically aligning the CEO's interests with shareholders, the CFO just planned to cash out $5 million, creating a terrible perception of 'executives taking the money, shareholders footing the bill'. $Hims & Hers Health(HIMS.US) $Defiance Daily Target 2X Long HIMS ETF(HIMZ.US)